Brooks Laboratories Limited (BOM:533543)

Market Cap	2.23B -46.4%
Revenue (ttm)	888.46M +15.4%
Net Income	216.03M
EPS	7.40
Shares Out	n/a
PE Ratio	10.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,903
Average Volume	11,265
Open	76.72
Previous Close	77.50
Day's Range	74.63 - 76.72
52-Week Range	59.00 - 165.95
Beta	n/a
RSI	58.67
Earnings Date	Feb 6, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 323
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 533543

Financial Performance

In fiscal year 2025, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2024.